AG真人官方

John Wiley & Sons, Inc. (WLYB) has filed a Form 144 indicating an intended sale of 5,665 shares of its common stock through UBS Financial Services on the NYSE, with an aggregate market value of $250,053. Based on the figures supplied, the reference price is roughly $44 per share. The shares to be sold represent approximately 0.013 % of the company鈥檚 44.62 million shares outstanding, making the planned disposition immaterial in percentage terms.

The stock was acquired via the vesting of multiple tranches of restricted stock units (RSUs) and performance share units (RPSUs) granted between April 2021 and April 2023. Tranche sizes range from 191 to 1,565 shares, reflecting normal equity-compensation practices. The filer reported no sales during the prior three-month period and certified the absence of undisclosed material adverse information.

Form 144 is a notice of proposed, not completed, sales. The filing does not disclose the seller鈥檚 identity, whether a Rule 10b5-1 trading plan exists, or final execution prices. Given the modest size of the transaction and its origin from routine incentive-compensation vesting, the event is unlikely to influence WLYB鈥檚 share price materially, but it remains a data point for investors monitoring insider-selling patterns.

Wayfair Inc. (symbol W) has filed a Form 144 indicating the intention to sell 180,943 Class A shares through Fidelity Brokerage Services on or about 01 July 2025. The shares carry an aggregate market value of $9.51 million and represent roughly 0.17 % of the company鈥檚 103.66 million shares outstanding.

The shares were originally acquired on 01 January 2002 as 鈥淔ounder Shares鈥� received as compensation. Within the past three months, related parties named in the filing鈥擲teven K. Conine and the Conine Family Foundation鈥攈ave already sold 153,963 shares for total gross proceeds of approximately $6.71 million.

• Proposed sale class: Class A
• Broker: Fidelity Brokerage Services LLC, Smithfield RI
• Exchange: NYSE
• Planned sale date: 07/01/2025
• Recent insider sales (last 3 months): ~154 k shares

While the dollar amount is sizeable, the percentage of outstanding shares is small, suggesting limited direct dilution. Nonetheless, the continued disposition of shares by founder-linked entities may influence investor sentiment.

Liquidia Corporation (Nasdaq: LQDA) filed a Form 8-K announcing the appointment of Dana Boyle as Chief Accounting Officer effective July 1, 2025. Boyle, 41, has led the company鈥檚 accounting function since January 2021 as SVP-Finance and Controller. Her background includes senior finance roles at Aerami Therapeutics and Aralez Pharmaceuticals, plus public-accounting experience at Deloitte & Touche. She is a licensed CPA (NY) and holds a B.S. in Accounting from Rutgers University.

Compensation package:

• Annual base salary: $425,000
• Target cash bonus: 50 % of base salary
• Equity award: Restricted Stock Units valued at $300,000 on the effective date. Vesting schedule: 25 % on July 11, 2026; remaining 75 % in equal quarterly installments over the following three years, subject to continued employment.

Severance terms: Under the Amended & Restated Executive Severance and Change in Control Plan, Boyle is entitled to up to 12 months of salary continuation, COBRA premium payments, and鈥攊f terminated within a change-in-control period鈥攁ccelerated vesting of 100 % of unvested equity plus target bonus payout.

The filing states that no family relationships or related-party transactions exist. The appointment was not made pursuant to any arrangement with other parties.

Investor take-away: While the event does not directly influence revenue or near-term financials, installing a seasoned CAO may enhance financial reporting quality and internal controls鈥攁n incremental positive for governance鈥恌ocused investors.

Thermo Fisher Scientific Inc. (TMO) filed a Form 4 on July 1, 2025 disclosing that director Jennifer M. Johnson was credited with 76.54 phantom stock units on June 28, 2025 under the company鈥檚 Deferred Compensation Plan for Directors. The units, valued at $408.28 each, convert to common stock on a 1-for-1 basis when the director leaves the board or upon a change of control. After the credit, Johnson holds 474.05 stock-equivalent units, all recorded as direct ownership.

The transaction represents routine deferral of quarterly board retainer fees rather than an open-market purchase or sale. With an estimated market value of roughly $31 thousand, the filing is financially immaterial relative to Thermo Fisher鈥檚 multi-billion-dollar market capitalization. No options were exercised, no common shares were sold, and the company鈥檚 share count and cash position remain unchanged. The filing nevertheless reinforces incentive alignment by tying a portion of Johnson鈥檚 compensation to future shareholder returns.